Effect of Adriamycin on Bone Marrow Cells
Author Information
Author(s): R. Bailey-Wood, C.M. Dallimore, J.A. Whittaker
Primary Institution: Welsh National School of Medicine and University Hospital of Wales
Hypothesis
The study examines the cytotoxic effects of Adriamycin on colony-forming unit granulocyte-macrophage (CFUGM) at varying plasma concentrations.
Conclusion
Adriamycin is more cytotoxic at low concentrations over longer periods than at high concentrations for short durations.
Supporting Evidence
- Adriamycin was found to have a 50% kill concentration of 23 nM for human CFUGM.
- Adriamycinol was less toxic with a 50% kill concentration of 80 nM.
- The aglycone of Adriamycin was inactive in the assays.
- Short-term exposure to 2 µM Adriamycin resulted in a loss of about 70% of CFUGM.
Takeaway
Adriamycin can kill cancer cells better when given in small amounts over a longer time instead of a lot at once.
Methodology
The study involved short-term pulse experiments and long-term incubations of bone marrow cells with Adriamycin and its metabolites.
Limitations
The results may only approximate the drug's effectiveness in vivo due to the rapid changes in plasma concentrations.
Participant Demographics
Bone marrow was obtained from haematologically normal patients undergoing thoracic surgery.
Want to read the original?
Access the complete publication on the publisher's website